Journal list menu

1. NAT10 is highly expressed in BLCA patients and its abnormal level predicts bladder cancer progression and low overall survival rate. NAT10 is necessary and sufficient for BLCA tumorigenic properties.

2. NAT10 is responsible for ac4C modification of target transcripts, including BCL9L, SOX4 and AKT1.

3. NAT10 may serve as an effective and novel therapeutic target for BLCA.

Comprehensive whole-genome bisulphite sequencing of prostate cancer tissue identified 1420 differentially methylated regions (DMRs) between patients with lethal disease versus non-lethal disease. DMRs were used to develop a targeted sequencing biomarker panel which validated cancer-specific methylation patterns in an independent cohort (n = 185). The epigenetic biomarker panel improves accuracy of identifying patients at risk of death compared to existing clinicopathological markers.

HFD-induced alteration of PIPs, especially PIP₃, may activate proliferative signaling transduction, such as the PI3K/AKT pathway through the upregulation of FASN, and influence PCa progression. Therefore, PI3K/AKT signaling and FASN could be the important targets for dietary intervention and/or chemoprevention in PCa incidence and progression.

Comprehensive understanding of survival differences in gender after cancer diagnosis is critical for cancer prevention and treatment. We compared the gender differences of cancer-specific survival in lung, esophageal, liver, pancreatic, stomach, colorectal, kidney, and bladder cancer. Totally, gender seemed to be a significant factor influencing cancer-specific survival, and the prognosis of female patients was better than male patients.

Ferredoxin 1 (FDX1) is a key gene in the process of Cuproptosis, and its expression level reflects the role of copper death in cell renal cell carcinoma (ccRCC) to a certain extent. For the first time, we used a combination of bioinformatics and experimental validation to explore the role of FDX1 in ccRCC prognosis, immunotherapy, and immune cell infiltration.

T-cell immunoglobulin and ITIM structural domain (TIGIT), a novel immune checkpoint, is widely expressed in a variety of immune cells. Recently studies have shown that TIGIT is extensively involved in various cancerous and noncancerous diseases such as chronic inflammation, autoimmune diseases, and abnormal pregnancy status. Thus, targeting TIGIT could be an effective immunotherapy option in the future.

Three gene fusions ERG (PMT. . PMT)_VEGFA (vascular endothelial growth factor A, EX8E. . END), TMPRSS2 (PMT. . IVS1)_ERG (IVS1. . END), and VEGFA (PMT. . IVS7)_TMPRSS2 (IVS1. . END) were identified in a patient's prostate cancer tissue. The administration of anlotinib, a tyrosine kinase inhibitor, in the combination of GnRHa (gonadotropin-releasing hormone agonist, Goserelin) and abiraterone not only reduced bone pain dramatically but also stabilized the disease for more than 2 years in the patient with these fusions.

We used the data of 12,394 kidney cancer patients in the SEER (surveillance, epidemiology, and final results) database to construct a research cohort, combine with statistical relevance and clinical experience to screen for factors related to kidney cancer survival and prognosis. Eight machine learning models (Support Vector Machines, Logistic Regression, Decision Trees, Random Forests, XGBoost, AdaBoost, K-Nearest Neighbors, and Multilayer Perceptrons) were developed to predict kidney cancer survival and tumor metastasis, using six indicators (Accuracy, Precision, Sensitivity, Specificity, F1 Score and AUROC) to validate, evaluate and optimize models. This study can provide decision support for early intervention in renal cancer patients.

This is a review on the effects of aging on biliary tract cancer (BTC). We discuss the potential link between aging and BTC from the aspects of molecular mechanisms (including the DNA damage repair (DDR), cell senescence and the tumour microenvironment (TME)) and clinical challenges.

There is a dynamic, bi-directional relationship between aging and cancer.

RFS and CSS did not significantly differ between the three groups, but OS was significantly poorer in patients ≥80 years old. Radical nephroureterectomy exerts the same anticancer effects in older patients as in younger patients and may be an option for patients aged ≥80 years who can tolerate surgery.

Here, we report that platinum doublet combination therapy may be beneficial in older patients with NSCLC. The OS was significantly longer in patients treated with platinum doublet combination therapy than in those who received monotherapy. Moreover, we identified several laboratory values that reflect prolonged exhaustion owing to inflammation and might be predictors of outcomes in older patients with NSCLC.

In older patients with extensive-stage small-cell lung cancer with performance status ≥3, carboplatin plus etoposide shrinks tumors, but provides shorter survival than in those with performance status 2.

Acrometastases of the hand are extremely rare and may be the first manifestation of lung cancer, but they consider a poor prognosis marker. It is important for physicians who encounter patients with a persistent lesion at the site of a wound located in the hand to earlier diagnosis. This recognition will improve patient care and may lead to earlier diagnosis of malignancy.

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.